Afatinib
- Generic Name
- Afatinib
- Brand Names
- Gilotrif, Giotrif
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O3
- CAS Number
- 850140-72-6
- Unique Ingredient Identifier
- 41UD74L59M
- Background
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...
- Indication
Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
- Associated Therapies
- -
Phase II Umbrella Study Directed by Next Generation Sequencing
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT03486509
Afatinib Osimertinib Sequencing NIS
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT03370770
- Locations
- 🇦🇹
Otto-Wagner Hospital, Vienna, Austria
Efficacy and Safety of Precision Therapy in Refractory Tumor
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Baodong Qin
- Target Recruit Count
- 300
- Registration Number
- NCT03239015
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT03157089
- Locations
- 🇫🇷
HOP Côte de Nacre, Caen, France
🇫🇷HOP Le Mans, Le Mans, France
🇺🇸Baptist Health Medical Group, Lexington, Kentucky, United States
Biomarker-based Study in R/M SCCHN
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2023-11-03
- Target Recruit Count
- 340
- Registration Number
- NCT03088059
- Locations
- 🇧🇪
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
🇮🇹IRCCS - Fondazione G. Pascale, Napoli, Italy
🇬🇧Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
Afatinib in Locally Advanced and Metastatic Chordoma
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT03083678
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
🇮🇹Istituto Nazionale dei Tumori: Fondazione IRCCS, Milan, Italy
🇳🇱Leiden University Medical Center, Leiden, Netherlands
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03054038
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT02979977
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.